Bronchodilators Market size was valued at USD 28,512.4 billion in 2021, growing at a CAGR of 5.4% from 2022-2028. The global market provides a detailed overview of the global bronchodilators market, and that can be segmented by drug class, by route of administration, by disease type, and by distribution channel. By drug class, the global bronchodilators market has been segmented into Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, and Combination Drugs. The Anticholinergics Inhibitors segment is likely to be the largest and fastest-growing segment in terms of drug class in 2021 and is expected to maintain the trend in the forecasted years. It is attributed to its wide application to treat chronic obstructive pulmonary disease. Based on route of administration, the global bronchodilators market is segmented into Oral Care Products, Parenteral, and Inhalation. Among these, the Oral segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on disease type, the global bronchodilators market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. The Asthma segment accounts for the largest share in 2021. Hosted segment is the second-largest share during the forecast period 2022-2028 period according to precision business insights. It is attributed to the increasing prevalence of asthma across the world. Based on distribution channel, the global bronchodilators market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment accounts for the largest share in 2021. Hospital pharmacies has very large patient base and prescribed medicines for hospital patients are boosting the growth in this segment. Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to lungs. These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting.
In Oct 2022, AeroRx Therapeutics partnered with HCmed Innovations to develop a new therapeutic combination of different classes of bronchodilators.